Trends in the use of cytoreductive nephrectomy in the united states

Clinical Genitourinary Cancer

Volumn 10, Issue 3, 2012, Pages 159-163

  Tsao, Che Kai ^a   Small, Alexander C ^a   Moshier, Erin L ^a   Gartrell, Benjamin A ^a   Wisnivesky, Juan P ^a   Sonpavde, Guru ^b,c   Godbold, James H ^a   Palese, Michael A ^a   Hall, Simon J ^a   Oh, William K ^a   Galsky, Matthew D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b TEXAS ONCOLOGY   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Kidney cancer; Renal cell carcinoma; Socioeconomic differences; Tyrosine kinase inhibitor

Indexed keywords

CYTOKINE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR TYROSINE KINASE INHIBITOR;

ARTICLE; CYTOREDUCTIVE NEPHRECTOMY; DRUG APPROVAL; EDUCATIONAL STATUS; FEMALE; GROUPS BY AGE; HEALTH INSURANCE; HOSPITAL; HUMAN; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; PREVALENCE; RACE; SOCIOECONOMICS; UNITED STATES;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; EDUCATIONAL STATUS; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEPHRECTOMY; SOCIOECONOMIC FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84865000928     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2012.03.008     Document Type: Article

References (24)

1. C. Coppin, F. Porzsolt, A. Awa Immunotherapy for advanced renal cell cancer Cochrane Database Syst Rev 2005 CD001425
2. R.T. Bennett, S.E. Lerner, H.C. Taub Cytoreductive surgery for stage IV renal cell carcinoma J Urol 154 1995 32 34
3. D.A. Levy, D.A. Swanson, J.W. Slaton Timely delivery of biological therapy after cytoreductive nephrectomy in carefully selected patients with metastatic renal cell carcinoma J Urol 159 1998 1168 1173 (Pubitemid 28172786)
4. R.C. Flanigan, S.E. Salmon, B.A. Blumenstein Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer N Engl J Med 345 2001 1655 1659 (Pubitemid 33126820)
5. G.H. Mickisch, A. Garin, H. van Poppel Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial Lancet 358 2001 966 970 (Pubitemid 32913522)
6. C. Jeldres, S. Baillargeon-Gagne, D. Liberman A population-based analysis of the rate of cytoreductive nephrectomy for metastatic renal cell carcinoma in the United States Urology 74 2009 837 841
7. National Cancer Data Base Benchmark Report 2011 http://www.facs.org/ cancer/ncdb/index.html Accessed: October 24, 2011
8. 7th ed. S.B. Edge, B.R. Byrd, C.C. Compton AJCC Cancer Staging Manual 2010 Springer New York, NY
9. S.L. Richey, S.H. Culp, E. Jonasch Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy Ann Oncol 22 2011 1048 1053
10. M. Sun, F. Abdollah, J. Schmitges et al. Cytoreductive nephrectomy in the elderly: a population-based cohort from the USA BJU Int September 27, 2011 10.1111/j.1464-410X.2011.10569.x published online
11. H.S. Stafford, S.L. Saltzstein, S. Shimasaki Racial/ethnic and gender disparities in renal cell carcinoma incidence and survival J Urol 179 2008 1704 1708
12. U.N. Vaishampayan, H. Do, M. Hussain Racial disparity in incidence patterns and outcome of kidney cancer Urology 62 2003 1012 1017 (Pubitemid 37510082)
13. L.A. Newman, K. Carolin, M. Simon Impact of breast carcinoma on African-American women: the Detroit experience Cancer 91 2001 1834 1843 (Pubitemid 32377972)
14. R.M. Hoffman, F.D. Gilliland, J.W. Eley Racial and ethnic differences in advanced-stage prostate cancer: the prostate cancer outcomes study J Natl Cancer Inst 93 2001 388 395 (Pubitemid 32229383)
15. J.D. Albano, E. Ward, A. Jemal Cancer mortality in the United States by education level and race J Natl Cancer Inst 99 2007 1384 1394 (Pubitemid 351767187)
16. Q.D. Trinh, J. Schmitges, M. Sun Morbidity and mortality of radical prostatectomy differs by insurance status Cancer 118 2012 1803 1810 10.1002/cncr.26475 Published online August 25, 2011
17. J. Kwok, S.M. Langevin, A. Argiris The impact of health insurance status on the survival of patients with head and neck cancer Cancer 116 2010 476 485
18. L. Zini, U. Capitanio, P. Perrotte Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma Urology 73 2009 342 346
19. R.L. O'Malley, K.A. Brewer, M.H. Hayn Impact of cytoreductive nephrectomy on eligibility for systemic treatment and effects on survival: are surgical complications or disease related factors responsible? Urology 78 2011 595 600
20. F. Abdollah, M. Sun, R. Thuret Mortality and morbidity after cytoreductive nephrectomy for metastatic renal cell carcinoma: a population-based study Ann Surg Oncol 18 2011 2988 2996
21. D. You, I.G. Jeong, J.H. Ahn The value of cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy J Urol 185 2011 54 59
22. T.K. Choueiri, W. Xie, C. Kollmannsberger The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy J Urol 185 2011 60 66
23. C.G. Wood, V. Margulis Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease Cancer 115 2009 2355 2360
24. B.F. Chapin, S.E. Delacroix Jr., S.H. Culp Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma Eur Urol 60 2011 964 971